CDK6 and lung carcinoma: Studies on other malignancies, including adrenocortical carcinoma [21], osteosarcoma [18], lung cancer [22], and nasopharyngeal carcinoma [23], have demonstrated overexpression of CDK4 and CDK6, which promote tumor progression and poor prognosis.